Sanofi-aventis said that Jevtana, an intravenously administered microtubule inhibitor, is approved in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-based treatment regimen.
Following the results from a Phase 3 Tropic clinical study involving patients with mHRPC previously treated with a docetaxel-containing treatment regimen, Jevtana in combination with prednisone has received approval.
Oliver Sartor, piltz professor for cancer research at Tulane Medical School, New Orleans, and North American principal investigator for the pivotal Tropic trial, said: “Jevtana is expected to help fill a treatment gap.”
Debasish Roychowdhury, senior vice president of global oncology at Sanofi-aventis, said: “The ability to introduce Jevtana for this patient population is an important achievement for sanofi-aventis Oncology.”